Actos (pioglitazone): a new treatment for type 2 diabetes
Authors:
- 1 July 2001
- journal article
- review article
- Published by IMR Press in Hospital Medicine
- Vol. 62 (7) , 411-416
Abstract
Type 2 diabetes is increasingly common and can be difficult to control. By directly targeting insulin resistance, the thiazolidinediones offer a new mode of treatment. Here, the pharmacology, clinical trial evidence, side-effects and current clinical uses of pioglitazone are reviewed.Keywords
This publication has 15 references indexed in Scilit:
- Safety and tolerability of pioglitazoneExperimental and Clinical Endocrinology & Diabetes, 2000
- Combining pioglitazone with a sulphonylurea or metformin in the management of type 2 diabetesExperimental and Clinical Endocrinology & Diabetes, 2000
- Pioglitazone in the treatment of type 2 diabetes mellitus: U.S. clinical experienceExperimental and Clinical Endocrinology & Diabetes, 2000
- Clinical pharmacokinetics of pioglitazoneExperimental and Clinical Endocrinology & Diabetes, 2000
- Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled studyClinical Therapeutics, 2000
- Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.Diabetes Care, 2000
- Thiazolidinediones: a new class of antidiabetic drugsDiabetic Medicine, 1999
- Cardiovascular Events and Their Reduction With Pravastatin in Diabetic and Glucose-Intolerant Myocardial Infarction Survivors With Average Cholesterol LevelsCirculation, 1998
- Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trialThe Lancet, 1998
- Diabetes and Cardiovascular DiseaseJAMA, 1979